文献速递淋巴瘤

循环肿瘤DNA评估大B细胞淋巴瘤疾病反应:liso-cel对比ASCT标准治疗

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.
PubMed 文献 · J Clin Oncol · 2026-04-27

TRANSFORM研究对比liso-cel与标准治疗(挽救免疫化疗、大剂量化疗、ASCT)在二线LBCL中的ctDNA分析,136例患者用PhasED-Seq检测。ctDNA清除(MRD阴性)在所有时间点预测更长EFS,liso-cel组更多患者达MRD阴性且EFS、PFS、缓解持续时间更优。ctDNA-MRD提供超越PET的预后价值。

要点

  • ctDNA清除(MRD阴性)在所有时间点预测更长EFS,两臂均如此
  • liso-cel组更多患者达MRD阴性,且EFS、PFS、缓解持续时间优于ASCT
  • ASCT后CR患者ctDNA再现可预测复发,ctDNA-MRD提供超越PET的预后价值

核心结论

  • liso-cel实现更深、更持久的ctDNA分子清除,与二线LBCL中优于ASCT的EFS和PFS一致。
  • ctDNA-MRD提供超越PET的预后价值,支持其作为治疗反应和复发预测的互补生物标志物。

研究设计与样本

  • TRANSFORM研究(NCT03575351)的关联性ctDNA分析,评估liso-cel对比标准治疗(挽救免疫化疗、大剂量化疗、ASCT)在二线LBCL中的表现。
  • 136例患者使用超敏感PhasED-Seq在预设时间点(随机分组、第43天、第64天、第126天)检测ctDNA。

主要发现

  • ctDNA清除(MRD阴性)在所有时间点预测两臂更长EFS,且liso-cel组达MRD阴性患者显著更多。
  • liso-cel在CR且MRD阴性患者中EFS、PFS和缓解持续时间优于ASCT。
  • ASCT后CR患者ctDNA再现证实其预测复发的潜力。
  • 调整PET反应后MRD阴性仍与EFS显著相关,交互检验显示PET状态与治疗臂对EFS存在显著交互。

关键数值与推荐

  • 136例患者使用PhasED-Seq在随机分组、第43天、第64天、第126天检测ctDNA。
  • ctDNA清除(MRD阴性)在所有时间点预测更长EFS,liso-cel组达MRD阴性患者显著更多。

临床怎么用

  • ctDNA-MRD可作为治疗反应和复发预测的互补生物标志物,提供超越PET的预后信息。
  • 在二线LBCL中,liso-cel较ASCT实现更深分子清除,与更优EFS和PFS一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report correlative circulating tumor DNA (ctDNA) analyses from TRANSFORM (ClinicalTrials.gov identifier: NCT03575351) evaluating lisocabtagene maraleucel (liso-cel) versus standard of care (salvage immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation [ASCT]) in second-line large B-cell lymphoma (LBCL). ctDNA association with efficacy was investigated at predefined time points (random assignment, day 43, day 64, and day 126 [3 months after liso-cel, approximately 2 months after ASCT]) for 136 patients using ultrasensitive PhasED-Seq. ctDNA clearance (measurable residual disease [MRD]neg) predicted longer event-free survival (EFS) at all time points in both arms, with significantly more liso-cel-treated patients achieving MRDneg. Liso-cel demonstrated superior outcomes versus ASCT, including longer EFS, progression-free survival (PFS), and duration of response among patients in complete response (CR) and MRDneg. ctDNA re-emergence in patients with CR after ASCT confirmed its potential in predicting relapse. MRDneg remained significantly associated with EFS after adjusting for positron emission tomography (PET) response, while interaction testing revealed a significant interaction between PET status and treatment arm for EFS. Liso-cel achieved deeper, more durable molecular clearance by ctDNA, consistent with superior EFS and PFS versus ASCT for second-line LBCL treatment. ctDNA-MRD provided prognostic value beyond PET, supporting its role as a complementary biomarker for treatment response and relapse prediction.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stepan L, Ansari S, Abramson JS, et al. Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. J Clin Oncol. 2026. PMID: 42044466. doi:10.1200/JCO-25-03051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。